<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042727</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2019-00250</org_study_id>
    <nct_id>NCT04042727</nct_id>
  </id_info>
  <brief_title>Controlling Rapid Atrial Fibrillation With Dexmedetomidine</brief_title>
  <acronym>C-RAD</acronym>
  <official_title>Controlling Rapid Atrial Fibrillation With Dexmedetomidine (C-RAD) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of Dexmedetomidine (DEX), on heart rate
      control in patients with rapid atrial fibrillation (AF) through a pragmatic, randomized,
      double blinded study comparing the addition of Dex or placebo to standard of care (SOC)
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine is a commonly used sedative/anxiolytic agent in the ICU with sympatholytic
      properties that can cause a decrease in heart rate. Eligible patients will be randomized into
      one of two groups: SOC plus Dex arm or SOC plus placebo (normal saline) arm. Study drug
      infusion will be administered at an infusion rate of 1Î¼g/kg/hr via IV, and will not include a
      loading dose. Four 6-second telemetry rhythm strips will be collected per hour, starting one
      hour prior to study drug infusion, during the eight hour infusion period, and two hours post
      infusion cessation). Degree of heart rate control and time to heart rate control for both
      groups will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2019</start_date>
  <completion_date type="Anticipated">June 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be randomized to receive either Dexmedetomidine or Placebo in addition to Standard of Care. Investigational pharmacy will be primarily responsible for randomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Ventricular Heart Rate</measure>
    <time_frame>Last 4 Hours of Study Drug Infusion</time_frame>
    <description>Compare degree of heart rate control between study and placebo arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Rhythm Strips with Heart Rate &lt;100 bpm</measure>
    <time_frame>Last 4 Hours of Study Drug Infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhythm Conversion</measure>
    <time_frame>Last 4 Hours of Study Drug Infusion</time_frame>
    <description>Compare number of patients converting to sinus rhythm in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Heart Rate Control</measure>
    <time_frame>During Study Drug Infusion</time_frame>
    <description>Compare the time to achieve an average Heart Rate &lt;100 bpm between the two arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparative need for rate control medications</measure>
    <time_frame>During Study Drug Infusion Period</time_frame>
    <description>Comparative Assessment of Rate Control Medications Administered Between Both Arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>During Study Drug Infusion Period</time_frame>
    <description>Assess mean systolic blood pressure measurements between the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for vasopressors used in both arms</measure>
    <time_frame>Study drug infusion period</time_frame>
    <description>Comparative assessment of vasopressors used in both arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rapid Atrial Fibrillation</condition>
  <condition>Heart Rate Control</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine plus Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine hydrochloride infusion will be prepared by the investigational pharmacy and administered intravenously at a rate of 1mcg/kg/hr for a duration of 8 hrs to patients in rapid Afib in addition to the usual standard of care as deemed necessary by patient's ICU team.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline solution will be prepared by investigational pharmacy and administered intravenously at a rate of 1mcg/kg/hr for a duration of 8 hrs to patients in rapid Afib in addition to the usual standard of care as deemed necessary by patient's ICU team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride</intervention_name>
    <description>Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.</description>
    <arm_group_label>Dexmedetomidine plus Standard of Care</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.5% sodium chloride (NaCl). The investigational pharmacy will prepare the normal saline placebo 250mL bag for infusion by patient's bedside nurse. Infusion will be 1mcg/kg/hr.</description>
    <arm_group_label>Placebo plus Standard of Care</arm_group_label>
    <other_name>Sodium Chloride Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients in a SBU Hospital ICU with rapid-AF (with ventricular rates &gt;100 bpm).

          -  Patient screening will be conducted prior to patient or LAR consent.

        Exclusion Criteria:

          -  Patients age &lt;18yrs;

          -  Anticipated ICU stay &lt;11hrs;

          -  Permanently paced heart rhythm;

          -  Known 2nd or 3rd degree heart block;

          -  Junctional rhythms;

          -  Known pregnancy;

          -  Known allergy to Dexmedetomidine;

          -  Receiving Dexmedetomidine prior to study onset;

          -  Non-intubated patients w/ Glasgow Coma Scale &lt;8;

          -  Weight &gt;400lbs (protocol dosing restriction);

          -  Untreated, symptomatic hypotension (SBP&lt;90mmHg);

          -  Received amiodarone, lidocaine, or mexileine w/in 4hrs prior to consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Mansour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Medical Intensive Care Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Mansour, MD</last_name>
    <phone>(631)-444-1755</phone>
    <email>mohamed.mansour@stonybrookmedicine.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto T Sanchez, B.S.</last_name>
      <phone>919-886-3587</phone>
      <email>roberto.sanchez@stonybrook.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Mohamed Mansour</investigator_full_name>
    <investigator_title>Director, Medical Intensive Care Unit</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Critical Care</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

